Zhixun Finance App News, Tibet Weixinkang Pharmaceutical (603676.SH) announced that its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd. (referred to as Baiyi Pharmaceutical) received the approval from the National Medical Products Administration for the issuance of the Notice of Approval for Supplementary Application for Compound Electrolyte Injection (Ⅱ), which passed the generic drug quality and efficacy consistency evaluation. Compound Electrolyte Injection (Ⅱ) is a compound preparation composed of multiple electrolytes, suitable for the treatment of isotonic dehydration with or anticipated acidosis, and replenishing lost extracellular fluid.